← Human Trials & Peer-Reviewed Studies
Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial
Plain-language guide to PMID 33939897 (2021): placebo-controlled randomized controlled trial study of L-Carnitine, fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 33939897
- Journal
- Journal of pediatric endocrinology & metabolism : JPEM
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Saneian H et al. (8 authors)
- DOI
- 10.1515/jpem-2020-0642
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at L-Carnitine in the context of fatty liver & elevated liver enzymes.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the pediatric population at global level.
Present study aims to assess the effect of l-carnitine supplementation on the NAFLD in children and adolescents.
Who Took Part
PubMed indexes the participants as young children, children and teenagers, both men and women.
Study was carried out in NAFLD participants (5-15 years).
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
The participants were allocated by chance, so the L-Carnitine group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with L-Carnitine could be set against what happens without it.
This randomized, triple-blind, placebo-controlled clinical trial was conducted in 2018-2019.
Liver enzymes and liver ultrasonography were assessed before and after the intervention.
Both groups received similar consultation for lifestyle changes.
What Was Measured
The subject headings attached to it are Alanine Transaminase, Aspartate Aminotransferases, Carnitine, Dietary Supplements and Non-alcoholic Fatty Liver Disease.
Author keywords: L-carnitine, children and nonalcoholic fatty liver disease.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of L-Carnitine in people with fatty liver & elevated liver enzymes.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2021 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.
More context: the L-Carnitine compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compound
L-Carnitine: An amino acid derivative that carries fatty acids into mitochondria for energy production.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.